Pharmacometrics Can Guide Further Trials, Minimize Risks – FDA Analysis
Executive Summary
Pharmacometric analysis can be used to refine the design of further studies following failed clinical trials, according to an analysis by reviewers in FDA's Office of Clinical Pharmacology & Biopharmaceutics
You may also be interested in...
What Not To Do: FDA Reviewer Talks Cancer Drug Development Mistakes
Using anonymous examples at the recent AACR meeting, FDA’s Tatiana Prowell highlights mistakes made and lessons learned in oncology drug reviews.
Can FDA Learn From Industry’s Risk/Benefit Decisions?
FDA is seeking insight into the pharmaceutical industry's pipeline management decisions as it works to improve its own risk/benefit analyses
Can FDA Learn From Industry’s Risk/Benefit Decisions?
FDA is seeking insight into the pharmaceutical industry's pipeline management decisions as it works to improve its own risk/benefit analyses